Business Context and Reporting Period
Company: Madrigal Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: June 20, 2017
Event: Entry into a Material Definitive Agreement for a private placement offering of securities.
Key Financial Metrics and Transaction Details
This filing details a capital raise rather than operational financial results. Key transaction metrics include:
- Gross Proceeds: Approximately $35,000,000 (before estimated offering expenses).
- Offering Price: $15.23 per share.
- Securities Issued:
- Approximately 328,300 shares of Common Stock.
- 1.97 million shares of Series A Convertible Preferred Stock.
- Conversion Terms: Series A Preferred Stock is convertible into Common Stock at a one-to-one ratio, subject to adjustments.
- Expected Closing: On or about June 23, 2017.
Note: The filing does not provide current revenue, profit, cash flow, margins, debt, or liquidity metrics for the company.
Material Changes and Transaction Structure
The primary material change is the execution of a Securities Purchase Agreement with a group of institutional accredited investors (existing non-controlling stockholders). Key structural elements include:
- Registration Obligations: The Company agreed to file a Form S-3 registration statement within 30 days of closing to register the resale of Common Stock issued in the Offering, with best efforts to have it declared effective within 90 days.
- Registration Rights: An Affiliate Registration Rights Agreement will be entered into if certain investors are deemed "affiliates," requiring the Company to file a registration statement within 60 days of investor demand.
- Exemption: The sale is conducted pursuant to Section 4(a)(2) of the Securities Act and Regulation D, without general solicitation.
Terms of Series A Preferred Stock and Risks
Series A Preferred Stock Features:
- Conversion Limitation: Holders cannot convert if the result would cause them (together with affiliates) to own more than 4.99% of the Common Stock, unless they provide 61 days' notice to adjust this percentage.
- Liquidation Preference: Participates pari passu with Common Stock holders (on an as-converted basis) after satisfaction of prior debts and liquidation preferences.
- Dividends: Entitled to receive dividends equal to those payable on Common Stock (on an as-converted basis) before other classes, excluding Common Stock dividends.
- Voting Rights: Generally no voting rights, except as required by law.
Risks and Contingencies:
- The securities have not been registered under the Securities Act of 1933 and cannot be resold absent registration or an exemption.
- The Offering is subject to customary closing conditions.
- Representations and warranties in the Purchase Agreement are for allocating contractual risk between parties and do not establish facts for investors.
Investor Verification Checklist
- Verify the final closing date and actual gross proceeds received after deducting offering expenses.
- Confirm the effectiveness of the Form S-3 registration statement filed within 30 days of closing.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific covenants and representations.
- Examine the Certificate of Designation (Exhibit 3.1) for detailed rights and limitations of the Series A Preferred Stock.
- Monitor the company's subsequent filings for updates on the use of proceeds and any changes to the capital structure.